Immunohistochemical expression of vascular endothelial growth factor a in advanced gallbladder carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 7, 2014, Pages 530-536

  Letelier, Pablo ^a   Garcia, Patricia ^b   Leal, Pamela ^a   Ili, Carmen ^a   Buchegger, Kurt ^a   Riquelme, Ismael ^a   Sandoval, Alejandra ^a   Tapia, Oscar ^a   Roa, Juan C ^a,b  

^a Molecular Pathology Laboratory Department of Pathology Scientific and Technological Bioresource Nucleus (BIOREN)   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

advanced gallbladder cancer; immunohistochemistry; prognostic biomarker; VEGF A

Indexed keywords

VASCULOTROPIN A; TUMOR MARKER; TUMOR PROTEIN; VEGFA PROTEIN, HUMAN;

ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CHRONIC CHOLECYSTITIS; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; FEMALE; FOLLOW UP; GALLBLADDER CARCINOMA; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE MICROARRAY; ADULT; BIOSYNTHESIS; CHOLECYSTITIS; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GALLBLADDER TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; CHOLECYSTITIS; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84906048363     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182a318a9     Document Type: Article

References (40)

1. Gourgiotis S, Kocher HM, Solaini L, et al. Gallbladder cancer. Am J Surg. 2008;196:252-264. (Pubitemid 351970506)
2. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001; 51:349-364. (Pubitemid 34232782)
3. Misra S, Chaturvedi A, Misra NC, et al. Carcinoma of the gallbladder. Lancet Oncol. 2003;4:167-176. (Pubitemid 36322307)
4. Roa I, Araya JC, Villaseca M, et al. Gallbladder cancer in a high risk area: morphological features and spread patterns. Hepatogastroenterology. 1999;46:1540-1546. (Pubitemid 29366293)
5. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012;6:172-187.
6. Donohue JH. Present status of the diagnosis and treatment of gallbladder carcinoma. J Hepatobiliary Pancreat Surg. 2001;8:530-534. (Pubitemid 33690571)
7. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001;26:25-35. (Pubitemid 32421949)
8. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932-936. (Pubitemid 43093958)
9. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676. (Pubitemid 36749215)
10. Goodsell DS. The molecular perspective: VEGF and angiogenesis. Stem Cells. 2003;21:118-119. (Pubitemid 36120373)
11. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407-424. (Pubitemid 28197463)
12. Karamysheva AF.Mechanisms of angiogenesis. Biochemistry (Mosc). 2008;73:751-762.
13. Mercurio AM, Bachelder RE, Bates RC, et al. Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin. Semin Cancer Biol. 2004;14:115-122. (Pubitemid 38234753)
14. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004;9(suppl 1):2-10. (Pubitemid 38747842)
15. Yamamoto S, Fujii K, Kitadai Y, et al. Expression of vascular endothelial growth factor in human gallbladder lesions. Oncol Rep. 1998;5:1065-1069. (Pubitemid 28372561)
16. Quan ZW, Wu K, Wang J, et al. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg. 2001;193:380-383. (Pubitemid 32895978)
17. Yue SQ, Yang YL, Zhou JS, et al. Relationship between urokinasetype plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer. World J Gastroenterol. 2004;10:2750-2752.
18. Zhi YH, Liu RS, Song MM, et al. Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol. 2005;11:3724-3728.
19. Tian Y, Ding RY, Zhi YH, et al. Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol. 2006;12:415-419. (Pubitemid 43329258)
20. Sergeant G, Lerut E, Ectors N, et al. The prognostic relevance of tumor hypoxia markers in resected carcinoma of the gallbladder. Eur J Surg Oncol. 2011;37:80-86.
21. Sun XN, Cao WG, Wang X, et al. Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma. Tumour Biol. 2011;32:1183-1190.
22. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011;34:1785-1788.
23. Ichihara E, Kiura K, Tanimoto M. Targeting angiogenesis in cancer therapy. Acta Med Okayama. 2011;65:353-362.
24. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-1474.
25. Alvarez H, Corvalan A, Roa JC, et al. Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer. Clin Cancer Res. 2008;14:2631-2638.
26. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185-188. (Pubitemid 24324908)
27. Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest. 2003;111:779-783. (Pubitemid 37074949)
28. Ferrara N, Houck K, Jakeman L, et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13:18-32.
29. Giatromanolaki A, Koukourakis MI, Simopoulos C, et al. Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol. 2003;29:879-883. (Pubitemid 37493287)
30. Batmunkh E, Shimada M, Morine Y, et al. Expression of hypoxiainducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma. Int J Clin Oncol. 2010;15:59-64.
31. Okita S, Kondoh S, Shiraishi K, et al. Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int J Oncol. 1998;12:1013-1018. (Pubitemid 28186759)
32. Liu Z, Jiang L, Yang B, et al. The roles of VEGF and C-myc in occurrence, development and metastasis of gallbladder carcinoma. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2003;20:68-70.
33. Harino Y, Imura S, Kanemura H, et al. Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase. Int J Clin Oncol. 2008;13:452-457.
34. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70:1493-1497.
35. Johnson LA, Lavin PT, Dayal YY, et al. Gallbladder adenocarcinoma: the prognostic significance of histologic grade. J Surg Oncol. 1987;34:16-18. (Pubitemid 17007161)
36. Tsukada K, Hatakeyama K, Kurosaki I, et al. Outcome of radical surgery for carcinoma of the gallbladder according to the TNM stage. Surgery. 1996;120:816-821.
37. White K, Kraybill WG, Lopez MJ. Primary carcinoma of the gallbladder: TNM staging and prognosis. J Surg Oncol. 1988;39: 251-255. (Pubitemid 19007287)
38. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94(suppl 10):1-26.
39. Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010;28:3491-3497.
40. Wiedmann MW, Mossner J. Molecular targeted therapy of biliary tract cancer-results of the first clinical studies. Curr Drug Targets. 2010;11:834-850.